Please provide your email address to receive an email when new articles are posted on . Lenalidomide maintenance therapy significantly improved PFS compared with observation among patients with newly ...

Data from a large phase III trial presented at the 2022 American Society of Hematology (ASH) annual meeting examined the relationship between minimal residual disease, progression-free survival, and ...

Lenalidomide (Revlimid)-induced second primary malignancies appear to be limited to patients with multiple myeloma, according to a systematic review and meta-analysis. While there was no significant ...

Move comes even as pricing pressure and regulatory complexity continue to weigh on global pharmaceutical markets.

New treatments for multiple myeloma have greatly increased survival, and this longer life expectancy has led to renewed concern about the risk for secondary malignancies. There was no difference in ...

Please provide your email address to receive an email when new articles are posted on . The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly ...

Our current focus remains on tirzepatide in terms of being the best‑in‑class molecule,” said Achin Gupta, Cipla’s Managing ...

Epcoritamab plus rituximab/lenalidomide significantly improved PFS and ORR compared with rituximab/lenalidomide alone. The Food and Drug Administration (FDA) has approved Epkinly ® (epcoritamab-bysp), ...

Multiple myeloma remains an incurable disease and novel treatments are urgently needed. Clinical studies have shown that lenalidomide is an effective treatment for patients with multiple myeloma. Two ...